• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Nature's Sunshine Reports Strong First Quarter 2024 Results

    5/7/24 4:05:00 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NATR alert in real time by email

    LEHI, Utah, May 07, 2024 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) (Nature's Sunshine), a leading natural health and wellness company offering high-quality herbal and nutritional products, reported financial results for the first quarter ended March 31, 2024.

    First Quarter 2024 Financial Summary vs. Same Year-Ago Quarter

    • Net sales were up 2% to $111.0 million compared to $108.6 million (up 4% in constant currency).
    • Gross margin increased 33 basis points to 71.2% compared to 70.8%.
    • GAAP net income attributable to common shareholders up significantly to $2.3 million, or $0.12 per diluted common share, compared to $0.9 million, or $0.04 per diluted common share.
    • Adjusted EBITDA up slightly to $9.2 million compared to $9.1 million.

    Management Commentary

    "In the first quarter, our omni-channel approach and high-quality products combined to drive momentum in our business," said Nature's Sunshine CEO Terrence Moorehead. "Specifically, we saw digital sales surge 33% with a 34% increase in new customers, helping our North American business unit grow 5% for the quarter. What's more, the successful launch of our new Power Line products helped drive improved performance in our European business that further reinforced our positive momentum.

    "These results were somewhat offset by slower sales in Asia/Pacific, which were up 5% in local currency, as the weak economic environment in China finally caught up with our positive sales momentum. Overall, our business continued to outpace the market as we delivered 4% revenue growth in local currency.

    "On the cost side of the equation, inflationary pressures and volatile foreign exchange rates have negatively impacted ingredient costs, placing additional pressure on our gross margin expansion efforts in the quarter, but we remain committed to deliver our $10 million cost of goods savings goal. We are also still firmly on our path to driving sustainable profit growth by expanding our ability to attract and retain customers."

    First Quarter 2024 Financial Results

      Net Sales by Operating Segment(Amounts in Thousands)
      Three Months

    Ended


    March 31, 2024
     Three Months

    Ended


    March 31, 2023
     Percent

    Change
     Impact of

    Currency

    Exchange
     Percent

    Change

    Excluding

    Impact of

    Currency
    Asia $46,220  $46,345  (0.3)% $(2,514) 5.2%
    Europe  22,296   21,405  4.2   493  1.9 
    North America  36,525   34,648  5.4   9  5.4 
    Latin America and Other  5,952   6,236  (4.6)  214  (8.0)
      $110,993  $108,634  2.2% $(1,798) 3.8%
                       

    Net sales in the first quarter increased 2% to $111.0 million compared to $108.6 million in the same year-ago quarter. Excluding the impact from foreign exchange rates, net sales in the first quarter of 2024 increased 3.8% compared to the year-ago quarter.

    Gross profit margin in the first quarter increased 33 basis points to 71.2% compared to 70.8% in the year-ago quarter. The increase was driven by improvements in market mix, price increases in various markets, and contribution margin improvement initiatives, partially offset by increases related to inflation and unfavorable foreign currency exchange.

    Volume incentives as a percentage of net sales were 30.2% compared to 30.5% in the year-ago quarter. The decrease was primarily due to changes in market mix.

    Selling, general and administrative expenses ("SG&A") in the first quarter were $40.8 million compared to $43.6 million in the year‐ago quarter. The decrease was driven primarily by a non-recurring loss in Japan in the prior year, partially offset by investments to drive digital growth. As a percentage of net sales, SG&A expenses were 36.7% for the first quarter of 2024 compared to 40.2% in the year-ago quarter.

    Operating income in the first quarter increased to $4.6 million, or 4.2% of net sales, compared to $0.2 million, or 0.2% of net sales, in the year-ago quarter.

    Other income, net, in the first quarter of 2024 was $31,000 compared to $1.5 million in the first quarter of 2023. Other income, net, primarily consists of foreign exchange gains as a result of net changes in foreign currencies. The provision for income taxes was $2.2 million in the first quarter of 2024 compared to $0.4 million for the year-ago quarter.

    GAAP net income attributable to common shareholders increased to $2.3 million, or $0.12 per diluted common share, compared to $0.9 million, or $0.04 per diluted common share, in the first quarter of 2023.

    Adjusted EBITDA in the first quarter increased slightly to $9.2 million compared to $9.1 million in the prior year quarter. The increase was driven primarily by the aforementioned increase in operating income. Adjusted EBITDA, which is a non-GAAP financial measure, is defined here as net income (loss) from continuing operations before taxes, depreciation, amortization, and other income (loss) adjusted to exclude share-based compensation expense and certain noted adjustments. A reconciliation of net income (loss) to adjusted EBITDA is provided in the attached financial tables.

    Balance Sheet and Cash Flow

    Net cash provided by operating activities was $2.2 million for the three months ended March 31, 2024, compared to $9.3 million in the prior year period. Capital expenditures during the three months ended March 31, 2024 totaled $3.7 million compared to $2.3 million in the comparable period of 2023. During the three months ended March 31, 2024, the Company repurchased 105,000 shares at a total cost of $1.8 million or $17.61 per share. As of March 31, 2024, the Company had cash and cash equivalents of $77.8 million and $2.1 million of debt.

    Outlook

    The Company continues to expect full year 2024 net sales to range between $455 - $480 million and adjusted EBITDA to range between $42 - $48 million.

    Conference Call

    The Company will hold a conference call today at 5:00 p.m. Eastern time to discuss its first quarter of 2024 results.

    Date: Tuesday, May 7, 2024

    Time: 5:00 p.m. Eastern time (3:00 p.m. Mountain time)

    Toll-free dial-in number: 1-888-886-7786

    International dial-in number: 1-416-764-8658

    Conference ID: 92920252

    Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Gateway Group at 1-949-574-3860.

    The conference call will be broadcast live and available for replay here and via the Events section of the Nature's Sunshine website here.

    A replay of the conference call will be available after 8:00 p.m. Eastern time on the same day through Tuesday, May 21, 2024.

    Toll-free replay number: 1-844-512-2921

    International replay number: 1-412-317-6671

    Replay ID: 92920252

    About Nature's Sunshine Products

    Nature's Sunshine Products (NASDAQ:NATR), a leading natural health and wellness company, markets and distributes nutritional and personal care products in more than 40 countries. Nature's Sunshine manufactures most of its products through its own state-of-the-art facilities to ensure its products continue to set the standard for the highest quality, safety and efficacy on the market today. Additional information about the company can be obtained at its website, www.naturessunshine.com.

    CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

    This press release contains forward-looking statements regarding the Company's future business expectations, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans, strategies and financial results, including expected improvements in gross profit and gross margin. All statements (other than statements of historical fact) that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements. These statements are often characterized by terminology such as "believe," "hope," "may," "anticipate," "should," "intend," "plan," "will," "expect," "estimate," "project," "positioned," "strategy" and similar expressions, and are based on assumptions and assessments made in light of our experience and perception of historical trends, current conditions, expected future developments and other factors we believe to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, including the following:

    • extensive government regulations to which the Company's products, business practices and manufacturing activities are subject;
    • registration of products for sale in foreign markets, or difficulty or increased cost of importing products into foreign markets;
    • legal challenges to the Company's direct selling program or to the classification of its independent consultants;
    • laws and regulations regarding direct selling may prohibit or restrict our ability to sell our products in some markets or require us to make changes to our business model in some markets;
    • liabilities and obligations arising from improper activity by the Company's independent consultants;
    • product liability claims;
    • impact of anti-bribery laws, including the U.S. Foreign Corrupt Practices Act;
    • the Company's ability to attract and retain independent consultants;
    • the loss of one or more key independent consultants who have a significant sales network;
    • potential for increased liability and compliance costs relating to the Company's joint venture for operations in China with Fosun Industrial Co., Ltd.;
    • the effect of fluctuating foreign exchange rates;
    • failure of the Company's independent consultants to comply with advertising laws;
    • changes to the Company's independent consultants compensation plans;
    • geopolitical issues and conflicts;
    • negative consequences resulting from difficult economic conditions, including the availability of liquidity or the willingness of the Company's customers to purchase products;
    • risks associated with the manufacturing of the Company's products;
    • supply chain disruptions, manufacturing interruptions or delays, or the failure to accurately forecast customer demand;
    • failure to timely and effectively obtain shipments of products from our manufacturers and deliver products to our independent consultants and customers;
    • world-wide slowdowns and delays related to supply chain, ingredient shortages and logistical challenges;
    • uncertainties relating to the application of transfer pricing, duties, value-added taxes, and other tax regulations, and changes thereto;
    • changes in tax laws, treaties or regulations, or their interpretation;
    • failure to maintain an effective system of internal controls over financial reporting;
    • cybersecurity threats and exposure to data loss;
    • the storage, processing, and use of data, some of which contain personal information, are subject to complex and evolving privacy and data protection laws and regulations;
    • reliance on information technology infrastructure; and
    • the sufficiency of trademarks and other intellectual property rights.

    These and other risks and uncertainties that could cause actual results to differ from predicted results are more fully detailed under the caption "Risk Factors" in our reports filed with the Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports filed on Form 10-Q.

    All forward-looking statements speak only as of the date of this press release and are expressly qualified in their entirety by the cautionary statements included in or incorporated by reference into this press release. Except as is required by law, the Company expressly disclaims any obligation to publicly release any revisions to forward-looking statements to reflect events after the date of this press release.

    Non-GAAP Financial Measures

    We have included information which has not been prepared in accordance with generally accepted accounting principles (GAAP), such as information concerning non-GAAP net income, adjusted EBITDA and net sales excluding the impact of foreign currency exchange fluctuations.

    We utilize the non-GAAP measures of non-GAAP net income and adjusted EBITDA in the evaluation of our operations and believe that these measures are useful indicators of our ability to fund our business. These non-GAAP financial measures should not be considered as an alternative to, or more meaningful than, U.S. GAAP net income (loss) as an indicator of our operating performance.

    Other companies may use the same or similarly named measures, but exclude different items, which may not provide investors with a comparable view of Nature's Sunshine Products' performance in relation to other companies. We have included a reconciliation of net income to adjusted EBITDA, the most comparable GAAP measure. We have also included a reconciliation of GAAP net income to non-GAAP net income and non-GAAP adjusted EPS, in the attached financial tables.

    Net sales in local currency removes, from net sales in U.S. dollars, the impact of changes in exchange rates between the U.S. dollar and the functional currencies of our foreign subsidiaries. This is accomplished by translating the current period net sales into U.S. dollars using the same foreign currency exchange rates that were used to translate the net sales for the previous comparable period.

    We believe presenting the impact of foreign currency fluctuations is useful to investors because it allows a more meaningful comparison of net sales of our foreign operations from period to period. Net sales excluding the impact of foreign currency fluctuations should not be considered in isolation or as an alternative to net sales in U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.

    With respect to our adjusted EBITDA outlook for the full year 2024, a quantitative reconciliation to the corresponding GAAP information cannot be provided without unreasonable effort because of the inherent difficulty of accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliation that have not yet occurred, are out of our control, or cannot be reasonably predicted, including but not limited to warrant liabilities and stock based compensation. For the same reasons, we are unable to assess the probable significance of the unavailable information, which could have a material impact on our future GAAP financial results.

    Investor Relations:

    Gateway Group, Inc.

    Cody Slach

    1-949-574-3860

    [email protected]

     
    NATURE'S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES
    CONDENSED CONSOLIDATED STATEMENTS OF INCOME
    (Amounts in thousands, except per share information)
    (Unaudited)
     
      Three Months Ended

    March 31,
       2024   2023 
    Net sales $110,993  $108,634 
    Cost of sales  32,015   31,692 
    Gross profit  78,978   76,942 
         
    Operating expenses:    
    Volume incentives  33,570   33,128 
    Selling, general and administrative  40,784   43,642 
    Operating income  4,624   172 
    Other Income, net  31   1,514 
    Income before provision for income taxes  4,655   1,686 
    Provision for income taxes  2,165   433 
    Net income  2,490   1,253 
    Net income attributable to noncontrolling interests  169   393 
    Net income attributable to common shareholders $2,321  $860 
         
    Basic and diluted net income per common share:    
         
    Basic earnings per share attributable to common shareholders $0.12  $0.05 
         
    Diluted earnings per share attributable to common shareholders $0.12  $0.04 
         
    Weighted average basic common shares outstanding  18,828   19,061 
    Weighted average diluted common shares outstanding  19,224   19,433 



    NATURE'S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES
    CONDENSED CONSOLIDATED BALANCE SHEETS
    (Amounts in thousands)
    (Unaudited)
     
      March 31,

    2024
     December 31,

    2023
    Assets    
    Current assets:    
    Cash and cash equivalents $77,773  $82,373 
    Accounts receivable, net of allowance for doubtful accounts of $138 and $142, respectively  9,694   8,827 
    Inventories  62,653   66,895 
    Prepaid expenses and other  10,036   7,722 
    Total current assets  160,156   165,817 
         
    Property, plant and equipment, net  45,271   45,000 
    Operating lease right-of-use assets  15,966   13,361 
    Investment securities - trading  802   747 
    Deferred income tax assets  15,278   15,064 
    Other assets  9,794   9,784 
    Total assets $247,267  $249,773 
         
    Liabilities and Shareholders' Equity    
    Current liabilities:    
    Accounts payable $9,029  $7,910 
    Accrued volume incentives and service fees  22,446   22,922 
    Accrued liabilities  23,257   33,162 
    Deferred revenue  1,877   1,794 
    Income taxes payable  7,208   6,418 
    Current portion of operating lease liabilities  5,064   4,547 
    Total current liabilities  68,881   76,753 
         
    Liability related to unrecognized tax benefits  624   312 
    Long-term portion of operating lease liabilities  12,648   10,376 
    Long-term note payable and revolving credit facility  2,107   — 
    Deferred compensation payable  802   747 
    Deferred income tax liabilities  1,515   1,401 
    Other liabilities  983   644 
    Total liabilities  87,560   90,233 
         
    Shareholders' equity:    
    Common stock, no par value, $50,000 shares authorized, $18,786 and $18,875 shares issued and outstanding, respectively  119,063   119,694 
    Retained earnings  52,032   49,711 
    Noncontrolling interest  5,651   5,482 
    Accumulated other comprehensive loss  (17,039)  (15,347)
    Total shareholders' equity  159,707   159,540 
    Total liabilities and shareholders' equity $247,267  $249,773 



    NATURE'S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES
    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
    (Amounts in thousands)
    (Unaudited)
     
      Three Months Ended

    March 31,
       2024   2023 
    CASH FLOWS FROM OPERATING ACTIVITIES:    
    Net income $2,490  $1,253 
    Adjustments to reconcile net income to net cash provided by operating activities:    
    Provision for doubtful accounts  —   4 
    Depreciation and amortization  3,160   2,805 
    Non-cash lease expense  1,197   932 
    Share-based compensation expense  1,369   1,058 
    Loss on sale of property, plant and equipment  —   71 
    Deferred income taxes  (157)  (631)
    Purchase of trading investment securities  (14)  — 
    Proceeds from sale of trading investment securities  21   31 
    Realized and unrealized gains on investments  (62)  (47)
    Foreign exchange losses (gains)  20   (1,477)
    Changes in assets and liabilities:    
    Accounts receivable  (1,136)  3,649 
    Inventories  3,389   457 
    Prepaid expenses and other current assets  (2,415)  (3,266)
    Other assets  (409)  (11)
    Accounts payable  1,099   2,391 
    Accrued volume incentives and service fees  (101)  781 
    Accrued liabilities  (6,802)  2,759 
    Deferred revenue  108   (1,142)
    Lease liabilities  (1,002)  (900)
    Income taxes payable  965   586 
    Liability related to unrecognized tax benefits  415   6 
    Deferred compensation payable  55   16 
    Net cash provided by operating activities  2,190   9,325 
    CASH FLOWS FROM INVESTING ACTIVITIES:    
    Purchases of property, plant and equipment  (3,689)  (2,325)
    Net cash used in investing activities  (3,689)  (2,325)
    CASH FLOWS FROM FINANCING ACTIVITIES:    
    Principal payments of long-term debt  —   (318)
    Proceeds from revolving credit facility  4,808   433 
    Principal payments of revolving credit facility  (2,701)  (283)
    Payments related to tax withholding for net-share settled equity awards  (152)  (165)
    Repurchase of common stock  (1,848)  (823)
    Net cash provided by (used in) financing activities  107   (1,156)
    Effect of exchange rates on cash and cash equivalents  (3,208)  (156)
    Net increase (decrease) in cash and cash equivalents  (4,600)  5,688 
    Cash and cash equivalents at the beginning of the period  82,373   60,032 
    Cash and cash equivalents at the end of the period $77,773  $65,720 
    SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:    
    Cash paid for income taxes, net of refunds $1,383  $1,991 
    Cash paid for interest  12   25 



    NATURE'S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES
    RECONCILIATION OF NET INCOME (LOSS) TO ADJUSTED EBITDA
    (Amounts in thousands)
    (Unaudited)
     
      Three Months Ended

    March 31,
       2024   2023 
    Net income $2,490  $1,253 
    Adjustments:    
    Depreciation and amortization  3,160   2,805 
    Share-based compensation expense  1,369   1,058 
    Other income, net*  (31)  (1,514)
    Provision for income taxes  2,165   433 
    Other adjustments (1)  —   5,098 
    Adjusted EBITDA $9,153  $9,133 
         
         
    (1) Other adjustments    
    Charge related to Japan loss  —   5,847 
    VAT refunds  —   (749)
    Total adjustments $—  $5,098 
     
    * Other loss, net is primarily comprised of foreign exchange (gains) losses, interest income, and interest expense.



    NATURE'S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES
    RECONCILIATION OF GAAP NET INCOME (LOSS) TO
    NON-GAAP NET INCOME and NON-GAAP ADJUSTED EPS
    (Amounts in thousands)
    (Unaudited)
     
      Three Months Ended

    March 31,
       2024   2023 
    Net income $2,490  $1,253 
    Adjustments:    
    Charge related to Japan loss  —   5,847 
    VAT Refund  —   (749)
    Tax impact of adjustments  —   (1,462)
    Total adjustments  —   3,636 
    Non-GAAP net income $2,490  $4,889 
         
    Reported income attributable to common shareholders $2,321  $860 
    Total adjustments  —   3,636 
    Non-GAAP net income attributable to common shareholders $2,321  $4,496 
         
    Basic income per share, as reported $0.12  $0.05 
    Total adjustments, net of tax  —   0.19 
    Basic income per share, as adjusted $0.12  $0.24 
         
    Diluted income per share, as reported $0.12  $0.04 
    Total adjustments, net of tax  —   0.19 
    Diluted income per share, as adjusted $0.12  $0.23 


    Primary Logo

    Get the next $NATR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NATR

    DatePrice TargetRatingAnalyst
    5/7/2025$19.00Buy
    DA Davidson
    9/13/2024$18.00Buy
    Canaccord Genuity
    3/9/2022$24.00 → $24.50Buy
    DA Davidson
    11/5/2021$22.00 → $24.00Buy
    DA Davidson
    10/15/2021$22.00Buy
    DA Davidson
    More analyst ratings

    $NATR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Nature's Sunshine Reports Strong First Quarter 2025 Results

      LEHI, Utah, May 06, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine"), a leading manufacturer of high-quality herbal and nutritional supplements, reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Summary vs. Same Year-Ago Quarter Net sales were up 2% to $113.2 million compared to $111.0 million (up 5% in constant currency).GAAP net income attributable to common shareholders was up 104% to $4.7 million, or $0.25 per diluted common share, compared to $2.3 million, or $0.12 per diluted common share.Adjusted EBITDA was up 20% to $11.0 million compared to $9.2 million. Capital Allocation Na

      5/6/25 4:05:00 PM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nature's Sunshine Appoints Heidi Wissmiller as Chairman of the Board

      LEHI, Utah, May 05, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR), a leading natural health and wellness company of high-quality herbal and nutritional products, today announced the appointment of Heidi Wissmiller as Chairman of the Board of Directors, effective April 30, 2025. She succeeds Richard D. Moss, who has retired after serving as a Director since 2018 and Chairman since 2022. Ms. Wissmiller has served on the Board of Nature's Sunshine since 2020. Over the course of her tenure, she has chaired the Governance and Risk Management Committees. As Chief Growth Officer at Rodan + Fields ("R+F"), the leading skincare brand in North America, Ms. Wissmiller led

      5/5/25 8:00:00 AM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nature's Sunshine Wins Two Stevie® Awards in the 2025 American Business Awards®

      LEHI, Utah, April 24, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR), a leading manufacturer of high-quality herbal and nutritional supplements, today announced it has been recognized with two prestigious Stevie® Awards in the 23rd Annual American Business Awards®. Nature's Sunshine received a Gold Stevie® Award for its 2023 Impact Report, which detailed the Company's achievements and progress in responsible business practices and sustainability. Additionally, the Company earned a Silver Stevie® Award for Achievement in Product Innovation for its new Chlorophyll Detoxifying Stick Packs. "We are deeply honored to be recognized by the American Business Awards," sai

      4/24/25 1:52:06 PM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NATR
    SEC Filings

    See more
    • SEC Form 10-Q filed by Nature's Sunshine Products Inc.

      10-Q - NATURES SUNSHINE PRODUCTS INC (0000275053) (Filer)

      5/6/25 5:10:24 PM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nature's Sunshine Products Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - NATURES SUNSHINE PRODUCTS INC (0000275053) (Filer)

      5/6/25 4:38:55 PM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Nature's Sunshine Products Inc.

      DEF 14A - NATURES SUNSHINE PRODUCTS INC (0000275053) (Filer)

      3/20/25 10:09:21 AM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NATR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • DA Davidson resumed coverage on Nature's Sunshine with a new price target

      DA Davidson resumed coverage of Nature's Sunshine with a rating of Buy and set a new price target of $19.00

      5/7/25 8:37:48 AM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity initiated coverage on Nature's Sunshine with a new price target

      Canaccord Genuity initiated coverage of Nature's Sunshine with a rating of Buy and set a new price target of $18.00

      9/13/24 7:38:59 AM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DA Davidson reiterated coverage on Natures Sunshine Products with a new price target

      DA Davidson reiterated coverage of Natures Sunshine Products with a rating of Buy and set a new price target of $24.50 from $24.00 previously

      3/9/22 9:23:08 AM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NATR
    Leadership Updates

    Live Leadership Updates

    See more
    • Nature's Sunshine Appoints Heidi Wissmiller as Chairman of the Board

      LEHI, Utah, May 05, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR), a leading natural health and wellness company of high-quality herbal and nutritional products, today announced the appointment of Heidi Wissmiller as Chairman of the Board of Directors, effective April 30, 2025. She succeeds Richard D. Moss, who has retired after serving as a Director since 2018 and Chairman since 2022. Ms. Wissmiller has served on the Board of Nature's Sunshine since 2020. Over the course of her tenure, she has chaired the Governance and Risk Management Committees. As Chief Growth Officer at Rodan + Fields ("R+F"), the leading skincare brand in North America, Ms. Wissmiller led

      5/5/25 8:00:00 AM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nature's Sunshine Appoints Katie A. May to Board of Directors

      LEHI, Utah, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (Nature's Sunshine) (NASDAQ:NATR), a leading manufacturer of high-quality herbal and nutritional supplements, today announced the appointment of Ms. Katie A. May to its board of directors effective January 30, 2025. Nature's Sunshine's board will now consist of ten directors with nine serving as independent directors. "Katie brings significant experience scaling and leading high-growth B2C, ecommerce and logistics companies," said Richard D. Moss, Chairman of the Board of Nature's Sunshine. "Her deep understanding of the full ecommerce lifecycle will strengthen and enhance our digital capabilities and drive s

      2/5/25 4:05:00 PM ET
      $NATR
      $PBI
      $STMP
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Office Equipment/Supplies/Services
      Miscellaneous
    • Nature's Sunshine Appoints Steven Fasching to Board of Directors

      LEHI, Utah, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (Nature's Sunshine) (NASDAQ:NATR), a leading manufacturer of high-quality herbal and nutritional supplements, today announced the appointment of Mr. Steven Fasching to its board of directors, effective November 6, 2024. Nature's Sunshine's board will now consist of nine directors with eight serving as independent directors. "We are delighted to welcome Steve to our expanded board of directors," said Richard D. Moss, Chairman of the Board for Nature's Sunshine. "He brings significant financial acumen and public company experience from well-known consumer brands and will be a valuable addition to our board. Ste

      11/11/24 4:05:00 PM ET
      $DECK
      $NATR
      Shoe Manufacturing
      Consumer Discretionary
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NATR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Fasching Steven J. was granted 8,000 shares, increasing direct ownership by 279% to 10,869 units (SEC Form 4)

      4 - NATURES SUNSHINE PRODUCTS INC (0000275053) (Issuer)

      5/7/25 1:25:23 PM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Straus Robert D was granted 8,000 shares, increasing direct ownership by 18% to 52,014 units (SEC Form 4)

      4 - NATURES SUNSHINE PRODUCTS INC (0000275053) (Issuer)

      5/6/25 3:42:40 PM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Roering Tess was granted 8,000 shares, increasing direct ownership by 36% to 29,927 units (SEC Form 4)

      4 - NATURES SUNSHINE PRODUCTS INC (0000275053) (Issuer)

      5/6/25 3:42:30 PM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NATR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Nature's Sunshine Products Inc. (Amendment)

      SC 13G/A - NATURES SUNSHINE PRODUCTS INC (0000275053) (Subject)

      2/12/24 10:37:49 AM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Nature's Sunshine Products Inc. (Amendment)

      SC 13G/A - NATURES SUNSHINE PRODUCTS INC (0000275053) (Subject)

      1/31/24 11:56:05 AM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Nature's Sunshine Products Inc. (Amendment)

      SC 13G/A - NATURES SUNSHINE PRODUCTS INC (0000275053) (Subject)

      2/13/23 2:42:04 PM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NATR
    Financials

    Live finance-specific insights

    See more
    • Nature's Sunshine Reports Strong First Quarter 2025 Results

      LEHI, Utah, May 06, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine"), a leading manufacturer of high-quality herbal and nutritional supplements, reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Summary vs. Same Year-Ago Quarter Net sales were up 2% to $113.2 million compared to $111.0 million (up 5% in constant currency).GAAP net income attributable to common shareholders was up 104% to $4.7 million, or $0.25 per diluted common share, compared to $2.3 million, or $0.12 per diluted common share.Adjusted EBITDA was up 20% to $11.0 million compared to $9.2 million. Capital Allocation Na

      5/6/25 4:05:00 PM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nature's Sunshine Sets First Quarter 2025 Conference Call for Tuesday, May 6, 2025, at 5:00 p.m. ET

      LEHI, Utah, April 22, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) (Nature's Sunshine), a leading manufacturer of high-quality herbal and nutritional supplements, will conduct a conference call on Tuesday, May 6, 2025, at 5:00 p.m. Eastern time (3:00 p.m. Mountain time) to discuss its financial results for the first quarter ended March 31, 2025. The company will report its financial results in a press release prior to the conference call. Nature's Sunshine CEO Terrence Moorehead and CFO Shane Jones will host the conference call, followed by a question and answer period. Date: Tuesday, May 6, 2025Time: 5:00 p.m. Eastern time (3:00 p.m. Mountain time)Toll-free di

      4/22/25 4:04:59 PM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nature's Sunshine Reports Fourth Quarter and Full Year 2024 Financial Results

      LEHI, Utah, March 11, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine" and/or the "Company"), a leading manufacturer of high-quality herbal and nutritional supplements, reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Summary vs. Same Year-Ago Quarter Net sales were up 8.5% to $118.2 million compared to $108.9 million (up 10.0% in constant currency).GAAP net loss attributable to common shareholders of $0.3 million, or $(0.02) per diluted share, compared to net income of $9.0 million, or $0.46 per diluted share.Adjusted EBITDA up 6% to $10.3 million com

      3/11/25 4:05:00 PM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care